Imaging of response to treatment in oncology;Imagerie de la réponse aux traitements en cancérologie

Journal de Radiologie

Volumn 88, Issue 6 C1, 2007, Pages 829-843

  Fournier, L S ^a   Cuenod C A ^a   Clement O ^a   Siauve, N ^a   Frija, G ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Cancer; Imaging, functional; RECIST; Therapy, response

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18;

CANCER CHEMOTHERAPY; CANCER PATIENT; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; DIFFUSION WEIGHTED IMAGING; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOLOGY; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; REVIEW; TISSUE DISTRIBUTION; TISSUE METABOLISM; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

EID: 34547631794     PISSN: 02210363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0221-0363(07)89885-4     Document Type: Short Survey

References (33)

1. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
2. WHO. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization; 1979. 45 p.
3. James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999;91:523-8.
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
5. Duffaud F, Therasse P. Nouvelles recommandations pour l'évaluation de la réponse tumorale dans les tumeurs solides. Bull Cancer 2000;87:881-6.
6. Mazumdar M, Smith A, Schwartz LH. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol 2004;57:358-65.
7. Tran LN, Brown MS, Goldin JG, et al. Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography. Acad Radiol 2004;11:1355-60.
8. Trillet-Lenoir V, Freyer G, Kaemmerlen P, et al. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol 2002;75:903-8.
9. Park JO, Lee SI, Song SY, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003;33:533-7.
10. Partridge SC, Gibbs JE, Lu Y, et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 2005;184:1774-81.
11. Tatum JL, Hoffman JM. Role of imaging in clinical trials of antiangiogenesis therapy in oncology. Acad Radiol 2000;7:798-9.
12. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
13. Batist G, Patenaude F, Champagne P, et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 2002;13:1259-63.
14. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10:6388S-92S.
15. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
16. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006;94:614-9.
17. Fournier LS, Novikov VY, Lucidi V, et al. MRI Monitoring for COX 2 Inhibition of Angiogenesis in a Breast Cancer Model. In: Radiology. Series MRI Monitoring for COX 2 Inhibition of Angiogenesis in a Breast Cancer Model. accepted under revision.
18. Ferrara KW, Merritt CR, Burns PN, et al. Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. Acad Radiol 2000;7:824-39.
19. Lassau N, Koscielny S, Opolon P et al. Evaluation of contrast-enhanced color Doppler ultrasound for the quantification of angiogenesis in vivo. Invest Radiol 2001;36:50-5.
20. de Bazelaire C, Rofsky NM, Duhamel G, et al. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma (1). Acad Radiol 2005;12:347-57.
21. Stejskal EO, Tanner J. Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys 1965;42:288-92.
22. Le Bihan D. Molecular diffusion, tissue microdynamics and microstructure. NMR Biomed 1995;8:375-86.
23. Ross BD, Moffat BA, Lawrence TS, et al. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2003;2:581-7.
24. Thoeny HC, De Keyzer F, Chen F, et al. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 2005;234:756-64.
25. Dzik-Jurasz AS, Murphy PS, George M, et al. Human rectal adenocarcinoma: demonstration of 1H-MR spectra in vivo at 1.5 T. Magn Reson Med 2002;47:809-11.
26. Shah N, Sattar A, Benanti M, Hollander S, Cheuck L. Magnetic resonance spectroscopy as an imaging tool for cancer: a review of the literature. J Am Osteopath Assoc 2006;106:23-7.
27. Galanaud D, Nicoli F, Figarella-Branger D, et al. Spectroscopie par résonance magnétique des tumeurs cérébrales. J Radiol 2006;87:822-32.
28. Taouli B. Le rôle de la spectroscopie IRM dans l'évaluation du cancer de la prostate. J Radiol 2006;87:222-7.
29. 3) spatial resolution. Radiology 1996;198:795-805.
30. Mueller-Lisse UG, Swanson MG, Vigneron DB, et al. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 2001;46:49-57.
31. Manton DJ, Chaturvedi A, Hubbard A, et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 2006;94:427-35.
32. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82.
33. Minn H, Leskinen-Kallio S, Lindholm P, et al. [18F] fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin. J Comput Assist Tomogr 1993;17:115-23.